[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336560-105":59,"doc-detail-336560-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","off-target-autophagy-inhibition-by-shp2-allosteric-inhibitors-contributes-to-their-antitumor-activity-in-ras-driven-cancers","Off-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their antitumor activity in RAS-driven cancers","","Aberrant activation of RAS/MAPK signaling drives many cancers, while inhibition strategies often trigger adaptive resistance that limits durable clinical benefit. SHP2 is a key node required for receptor tyrosine kinase–mediated RAS activation and is therefore a target of SHP2 allosteric inhibitors. The study identifies an unrecognized off-target effect: SHP2 allosteric inhibitors accumulate in lysosomes and block autophagic flux independently of SHP2. This off-target autophagy inhibition strengthens antitumor activity and helps overcome resistance mechanisms such as MAPK rebound and protective autophagy, enabling an on- and off-target therapeutic framework for mutant RAS malignancies including pancreatic and colorectal cancers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/off-target-autophagy-inhibition-by-shp2-allosteric-inhibitors-contributes-to-their-antitumor-activity-in-ras-driven-cancers/336560/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/off-target-autophagy-inhibition-by-shp2-allosteric-inhibitors-contributes-to-their-antitumor-activity-in-ras-driven-cancers/336560.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What off-target effect do SHP2 allosteric inhibitors have in this study?","Question",{"text":112,"@type":113},"They accumulate in lysosomes and block autophagic flux in an SHP2-independent manner.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does off-target autophagy inhibition influence antitumor activity?",{"text":117,"@type":113},"It contributes to the antitumor activity of SHP2 allosteric inhibitors in RAS-driven cancers.",{"name":119,"@type":110,"acceptedAnswer":120},"What resistance mechanisms can SHP2 allosteric inhibitors overcome?",{"text":121,"@type":113},"They can overcome drug resistance such as MAPK rebound and protective autophagy induced by RAS/MAPK pathway blockage.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336560,1790073283,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","The Journal of Clinical Investigation RESEAR CH ARTICLE  \nOff-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their antitumor activity in RAS-driven cancers  \nYiming Miao,1 Yunpeng Bai,1 Jinmin Miao,1 Allison A. Murray,1 Jianping Lin,1 Jiajun Dong,1 Zihan Qu,2 Ruo-Yu Zhang,1 Quyen D. Nguyen,2 Shaomeng Wang,3 Jingmei Yu,1 Frederick Nguele Meke,1 and Zhong-Yin Zhang1,2,4,5  \n1Department of Medicinal Chemistry and Molecular Pharmacology and 2Department of Chemistry, Purdue University, West Lafayette, Indiana, USA. 3Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan, USA. 4Institute for Cancer Research and 5Institute for Drug Discovery, Purdue University, West Lafayette, Indiana, USA.  \nAberrant activation of RAS/MAPK signaling is common in cancer, and efforts to inhibit pathway components have yielded drugs with promising clinical activities. Unfortunately, treatment-provoked adaptive resistance mechanisms inevitably develop, limiting their therapeutic potential. As a central node essential for receptor tyrosine kinase–mediated RAS activation, SHP2 has emerged as an attractive cancer target. Consequently, many SHP2 allosteric inhibitors are now in clinical testing. Here we discovered a previously unrecognized off-target effect associated with SHP2 allosteric inhibitors. We found that these inhibitors accumulate in the lysosome and block autophagic flux in an SHP2-independent manner. We showed that off-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their antitumor activity. We also demonstrated that SHP2 allosteric inhibitors harboring this off-target activity not only suppress oncogenic RAS signaling but also overcome drug resistance such as MAPK rebound and protective autophagy in response to RAS/MAPK pathway blockage. Finally, we exemplified a therapeutic framework that harnesses both the on-and off-target activities of SHP2 allosteric inhibitors for improved treatment of mutant RAS–driven and drug-resistant malignancies such as pancreatic and colorectal cancers.  \nIntroduction  \nAs membrane-bound small GTPases cycling between active GTPbound and inactive GDP-bound states, the rat sarcoma (RAS) proteins serve as critical molecular switches in response to diverse extracellular stimuli, including growth factors (1) . Activated RAS interacts with distinct effector proteins, thereby regulating diverse cytoplasmic signaling networks and cellular processes (1, 2) . As one of the best-studied signaling pathways, the growth factor receptor–mediated RAS/RAF/MEK1/2/ERK1/2/MAPK cascade plays an essential role in cell proliferation, survival, and differentiation (3). Not surprisingly, this signaling process is aberrantly activatedin 46% of all cancer types in The Cancer Genome Atlas datasets (4). Moreover, gain-of-function mutations in RAS rank among the most frequently observed genetic lesions in human cancers (1, 5), and the KRAS isoform alone is mutated in 9% of cancer cases, with high frequency in pancreatic ductal adenocarcinoma (72%), genomically stable colorectal cancer (69%), and non–small cell lung cancer (33%) (4). Accordingly, substantial efforts have been devoted to targeting the receptor tyrosine kinase (RTK)/RAS/ MAPK pathway (6), yielding numerous small-molecule inhibitors of pathway components RTKs, KRAS, RAF, MEK1/2, and ERK1/2  \nAuthorship note: YM and YB contributed equally to this work.  \nConflict of interest: ZYZ is an academic cofounder of Tyligand Bioscience. Copyright: © 2024, Miao et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.  \nSubmitted: October 31, 2023; Accepted: June 4, 2024; Published: June 6, 2024.  \nReference information: J Clin Invest. 2024;134(15):e177142 .  \n[https://doi.org/10.1172/JCI177142](https://doi.org/10.1172/JCI177142) .  \nthat show efficacy in cancer patients (7–10). Unfortunately, the enthusiasm asso","cbCaick9IUMoThm9","https://ap.wps.com/l/cbCaick9IUMoThm9","pdf",19530676,15,"English","# Introduction\n## RAS/MAPK signaling and therapeutic resistance\n## SHP2 regulation and rationale for inhibition","[{\"question\":\"What off-target effect do SHP2 allosteric inhibitors have in this study?\",\"answer\":\"They accumulate in lysosomes and block autophagic flux in an SHP2-independent manner.\"},{\"question\":\"How does off-target autophagy inhibition influence antitumor activity?\",\"answer\":\"It contributes to the antitumor activity of SHP2 allosteric inhibitors in RAS-driven cancers.\"},{\"question\":\"What resistance mechanisms can SHP2 allosteric inhibitors overcome?\",\"answer\":\"They can overcome drug resistance such as MAPK rebound and protective autophagy induced by RAS/MAPK pathway blockage.\"}]","Off-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their antitumor activity in RAS-driven cancers | PDF",1790015604,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bda47f7f253e23adbfd0e3ad9b80096a.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09606095ada898a11bd0108b23972c2a.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31efd28ded003f525ec90538a2a6d371.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb58c2a23f3577475d9bbfc387c1da49.webp",980,1311]